163 related articles for article (PubMed ID: 28294892)
1. [Assessment of Efficacy and Safety of Metabolic Therapy With Trimetazidine MB in Patients With Ischemic Heart Disease and Chronic Heart Failure].
Gorbunova ML; Vilkova AV
Kardiologiia; 2016 Mar; 56(3):67-72. PubMed ID: 28294892
[TBL] [Abstract][Full Text] [Related]
2. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
Belardinelli R
Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
[TBL] [Abstract][Full Text] [Related]
3. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study.
El-Kady T; El-Sabban K; Gabaly M; Sabry A; Abdel-Hady S
Am J Cardiovasc Drugs; 2005; 5(4):271-8. PubMed ID: 15984909
[TBL] [Abstract][Full Text] [Related]
4. [Trimetazidine in correction of chronic heart failure in patients with ischemic heart disease].
Nedoshivin AO; Kutuzova AE; Nesterova IV; Mikhaĭlova IE; Rubashkina EI; Novikova NA; Liasnikova EA; Perepech NB
Kardiologiia; 2002; 42(3):12-5. PubMed ID: 12494179
[TBL] [Abstract][Full Text] [Related]
5. Metabolic management of ischemic heart disease: clinical data with trimetazidine.
Desideri A; Celegon L
Am J Cardiol; 1998 Sep; 82(5A):50K-53K. PubMed ID: 9737486
[TBL] [Abstract][Full Text] [Related]
6. [Correction of episodes of transitory myocardial ischemia with trimetazidine in patients with ischemic heart disease combined with type 2 diabetes mellitus].
Petriĭ VV; Mikova NV; Makolkin VI
Kardiologiia; 2007; 47(7):22-5. PubMed ID: 18260890
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of long-term therapy with trimetazidine in patients with ischemic heart disease in combination with chronic obstructive pulmonary disease].
Kolomoets NM; Baksheev VI; Zarubina EG; Uvaĭsova IU
Kardiologiia; 2008; 48(2):47-51. PubMed ID: 18261009
[No Abstract] [Full Text] [Related]
8. [Clinical efficacy of combined therapy with enalapril + trimetazidine in patients with hypertension comorbid with ischemic heart disease and metabolic disturbances].
Petelina TI; Gapon LI; Bakhmatova IuA; Zhevagina IA
Ter Arkh; 2005; 77(8):19-23. PubMed ID: 16206600
[TBL] [Abstract][Full Text] [Related]
9. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
[TBL] [Abstract][Full Text] [Related]
10. Trimetazidine improves recovery during reperfusion in isolated rat hearts after prolonged ischemia.
Ikizler M; Dernek S; Sevin B; Kural T
Anadolu Kardiyol Derg; 2003 Dec; 3(4):303-8. PubMed ID: 14675878
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of myocardial cytoprotector trimetazidine in peri- and postmenopausal women with ischemic heart disease].
Churshin AD; Pimenov LT
Kardiologiia; 2003; 43(8):31-5. PubMed ID: 14593380
[TBL] [Abstract][Full Text] [Related]
12. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris.
Shlyakhto EV; Almazov VV; Nifontov EM; Vakhrameyeva IV; Rudomanov OG; Zakharov DV; Kazarin VV; Vakhrameyeva NV
Am J Cardiovasc Drugs; 2002; 2(2):119-24. PubMed ID: 14727987
[TBL] [Abstract][Full Text] [Related]
13. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
Di Napoli P; Di Giovanni P; Gaeta MA; Taccardi AA; Barsotti A
J Cardiovasc Pharmacol; 2007 Nov; 50(5):585-9. PubMed ID: 18030070
[TBL] [Abstract][Full Text] [Related]
14. The role of metabolic therapy with trimetazidine in effort tolerance in patients with ischemic heart disease.
Suljić U; Prnjavorac B; Bego T; Malenica M; Dujić T; Prnjavorac I; Čaušević A; Šaranović L
Med Glas (Zenica); 2018 Aug; 15(2):109-114. PubMed ID: 30047538
[TBL] [Abstract][Full Text] [Related]
15. Effect of trimetazidine on the functional capacity of ischemic heart disease patients not suitable for revascularization: Meta-analysis of randomized controlled trials.
Ajabnoor A; Mukhtar A
PLoS One; 2022; 17(2):e0263932. PubMed ID: 35148340
[TBL] [Abstract][Full Text] [Related]
16. [Enhancement of antioxidant status of the elderly patients with ischemic heart disease in response to amino acid composition of MP-33 in combined therapy with trimetazidine].
Kalinina EB; Komissarova IA; Zaslavskaia RM; Zhdanov IuA
Klin Med (Mosk); 2002; 80(5):50-3. PubMed ID: 12087889
[TBL] [Abstract][Full Text] [Related]
17. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1.
Szwed H; Sadowski Z; Pachocki R; Domzał-Bocheńska M; Szymczak K; Szydłowski Z; Paradowski A; Gajos G; Kałuza G; Kulon I; Wator-Brzezińska A; Elikowski W; Kuźniak M
Cardiovasc Drugs Ther; 1999 May; 13(3):217-22. PubMed ID: 10439884
[TBL] [Abstract][Full Text] [Related]
18. Role of trimetazidine in management of ischemic cardiomyopathy.
Bertomeu-Gonzalez V; Bouzas-Mosquera A; Kaski JC
Am J Cardiol; 2006 Sep; 98(5A):19J-24J. PubMed ID: 16931202
[TBL] [Abstract][Full Text] [Related]
19. Meeting the challenge of chronic ischaemic heart disease with trimetazidine.
Marzilli M; Affinito S
Coron Artery Dis; 2005 Nov; 16 Suppl 1():S23-7. PubMed ID: 16340400
[TBL] [Abstract][Full Text] [Related]
20. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease.
Rehberger-Likozar A; Šebeštjen M
Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
